BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Ohr Pharmaceutical (OHRP) Announces Addition of Dr. John Wroblewski to Ophthalmic Scientific Advisory Board


8/7/2013 7:58:23 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK, Aug. 7, 2013 /PRNewswire/ -- Ohr Pharmaceutical Inc. (NasdaqCM: OHRP) today announced the addition of John J. Wroblewski M.D. to its Scientific Advisory Board ("SAB"). The board, comprised of leading retinal ophthalmology experts, advises the company on its clinical programs, regulatory strategy and provides strategic guidance to support the ongoing development of lead drug candidate Squalamine in multiple neovascular ophthalmic clinical indications, each with sizable commercial markets.

"Squalamine eye drops have the potential to significantly advance the treatment of wet-AMD through a unique mechanism of action which may provide distinct or additional benefits to the anti-VEGF agents currently used to treat these patients," stated Dr. John Wroblewski, retina specialist at Cumberland Valley Retina Consultants. "I am excited to be participating in the OHR-002 wet-AMD clinical trial and look forward to working closely with the Ohr team to evaluate Squalamine eye drops in additional ophthalmic indications where neovascularization plays an important role."

Irach B. Taraporewala, Ph.D., CEO of Ohr Pharmaceutical, commented, "We are delighted to be working with a thought leader and clinical researcher of Dr. Wroblewski's caliber. Our OHR-002 trial to evaluate Squalamine eye drops in wet-AMD continues to progress well, as evidenced by our recently announced completion of the halfway point in enrollment, and the expected availability of interim data in the second quarter of 2014. We look forward to the contributions Dr. Wroblewski will make during this exciting time for Ohr Pharmaceutical."

John Joseph Wroblewski, M. D., is a board-certified ophthalmologist who has been treating diseases of the retina, macula, and vitreous for twenty-two years. He is the senior partner of Cumberland Valley Retina Consultants located in Western Maryland and South-Central Pennsylvania. Doctor Wroblewski is a graduate of the Moorfields Eye Hospital in London, England, and has served as a consultant and medical advisor to several ophthalmic pharmaceutical companies. He has participated in the design of multiple clinical protocols and has been a Principal Investigator in twenty-three national clinical trials conducted over the past twelve years, all of which investigated the efficacy of different pharmaceutical agents in the treatment of exudative macular degeneration, retinal vein occlusion, and diabetic retinopathy. Doctor Wroblewski has lectured nationally and internationally and is the founder and president of Retina Care International, a not-for-profit organization actively working since 2005 to help solve the diabetic retinopathy pandemic in the Yucatan Peninsula in Mexico. Dr. Wroblewski received his M.D. from Georgetown University School of Medicine.

About Squalamine Eye Drops
Squalamine is an anti-angiogenic small molecule with a novel intracellular mechanism of action, which counteracts multiple growth factors implicated in the angiogenesis process. Ohr Pharmaceutical has developed a novel eye drop formulation of Squalamine for the treatment of wet-AMD, designed for self-administration, which may provide several potential advantages over the FDA approved current standards of care which require intravitreal injections directly into the eye. The drug, using an intravenous administration in over 250 patients in Phase I and Phase II trials for the treatment of wet-AMD, showed favorable biological effect and maintained and improved visual acuity outcomes. In May 2012, the Squalamine Eye Drop program was granted Fast Track Designation by the U.S. FDA. A Phase II randomized, double blind, placebo controlled study (OHR-002) to evaluate the efficacy and safety of Squalamine Eye Drops for the treatment of wet-AMD is currently enrolling patients at more than twenty clinical sites in the U.S.

About Ohr Pharmaceutical Inc.
Ohr Pharmaceutical, Inc. (NasdaqCM:OHRP) is a pharmaceutical company dedicated to the clinical development of new drugs for underserved therapeutic needs in large and growing markets. The Company is focused on advancing its pipeline products currently in phase II clinical development: Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration, and OHR/AVR118 for the treatment of cancer cachexia. Additional information on the Company can be found at www.ohrpharmaceutical.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as the date thereof, and Ohr Pharmaceutical undertakes no obligation to update or revise the forward-looking statement whether as a result of new information, future events or otherwise. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, the financial resources available to us, and general economic conditions. For example, there can be no assurance that Ohr will be able to sustain operations for expected periods. Shareholders and prospective investors are cautioned that no assurance of the efficacy of pharmaceutical products can be claimed or assured until final testing; and no assurance or warranty can be made that the FDA or Health Canada will approve final testing or marketing of any pharmaceutical product. Ohr's most recent Annual Report and subsequent Quarterly Reports discuss some of the important risk factors that may affect our business, results of operations and financial condition. We disclaim any intent to revise or update publicly any forward-looking statements for any reason.

Contact:
Investor Relations:
Tel: (877) 215-4813
Email: ir@ohrpharmaceutical.com

SOURCE Ohr Pharmaceutical Inc.



Hey, check out all the research scientist jobs. Post your resume today!


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES